oral glp 1 meds GLP-1s rapidly expanding user base Feel fuller Oral GLP-1: how to win

FDA announced it is considering removing GLP-1 medications from the 503B bulks list

Manufacturing capacity has emerged as an equally important competitive moat

Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy and Ozempic

Medical guidance is also essential for people experiencing side effects or managing conditions such as pregnancy, pancreatitis, or thyroid-related risks 7

Richard DiMarchi, one of the pioneers of GLP-1 drugs, argues that the degree which they have helped to manage excess body weight compares with the historic breakthroughs in the management of excess blood pressure, excess lipids and excess glucose